TrialJournal of patient-reported outcomes2024

Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.

Priya S Kishnani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.